Fig. 6

HGF/c-Met/Akt enhances the pathogenic effects of FLSs in RA. a IL-6 production and clonogenic ability of FLSs after treatment with HGF and/or DMSO (solvent control), JNJ-388777605 (c-Met pathway inhibitor), LY294002 (Akt pathway inhibitor), or YM-155 (survivin expression inhibitor). * represents p < 0.05 (other groups vs. HGF treatment group). ** represent p < 0.01 (other groups vs. HGF treatment group). b Cell cycle analysis after treatment with different inhibitors is shown. PI staining was utilized after treatment. c Western blot and IOD analysis results are shown of proteins expressed in FLSs after specific treatments. Cell lysates were analyzed by western blotting. IODs were analyzed by Image Pro Plus 6. “Relative IOD” represents the IOD of a specific protein divided by the IOD of GAPDH